Medifirst Solutions, Inc. (OTCMKTS:MFST) provided an update on the Company’s activities. A partnership with a California medical facility that offers Medical Cannabis Evaluations is in the final stages, and a new product that generates water by using an advanced patented technology will be unveiled at the IECSC Conference at the NYC Javits Center.

As quoted in the press release:

The center which offers Holistic Evaluation is a new evaluation clinic offering medical cannabis recommendations to qualified patients who wish to seek alternative options to using pharmaceutical drugs to treat or manage their medical condition or illness.

As previously announced, Medifirst will also be unveiling several exciting new products at the IECSC Conference at the NYC Javits Center March 9th to 11th. The company is pleased to announce that is has completed an agreement with Atmospheric Water Solution, a Florida based company that generates water by using an advanced patented technology. The water generating machines extract water directly from the air we breathe.

Medifirst Solutions CEO, Bruce J. Schoengood, said:

Our most recent press announcement gave shareholders a framework of our plans for growth and expansion. I am pleased and excited to announce that we have completed an agreement to add an innovative product that will immediately add both revenue to our balance sheet and a new line of products to our health and wellness division. The company also continues to make substantial and fast progress in creating business opportunities and inroads into the legal marijuana industry.

Click here to read the Medifirst Solutions Inc. (OTCQB:MFST) press release

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less